Liposorber® LA-15 system for LDL apheresis in resistant nephrotic syndrome patients.
Mohammad F Al-MousilyOana NicoaraDavid T SelewskiKatherine TwombleyPublished in: Pediatric nephrology (Berlin, Germany) (2021)
LDL-A was able to significantly decrease the lipid levels in these patients and induce CR and PR in the majority. The current study confirms previous studies showing those with a higher glomerular sclerosis burden were less likely to respond. LDL-A should be considered in patients with treatment-resistant SRNS and should be considered before there is a high burden of glomerular sclerosis to provide the best chance of success.